Towheed T E, Judd M J, Hochberg M C, Wells G
Medicine and Community Health and Epidemiology, Queen's University, Room 2066, Etherington Hall, Department of Medicine, Queen's University, Kingston, Ontario, Canada, K7L 3N6.
Cochrane Database Syst Rev. 2003(2):CD004257. doi: 10.1002/14651858.CD004257.
Osteoarthritis (OA) is the most common form of arthritis. Published guidelines and expert opinion are divided over the relative role of acetaminophen (also called paracetamol or Tylenol) and non-steroidal anti-inflammatory drugs (NSAIDs) as first-line pharmacologic therapy. The comparative safety of acetaminophen and NSAIDs is important to consider as NSAIDs have the potential for serious gastrointestinal, renal, and cardiovascular toxicities, and acetaminophen in high dosages (greater than or equal to 2 grams per day), may also have the potential for serious upper gastrointestinal toxicity.
To assess the efficacy and safety of acetaminophen versus placebo and versus NSAIDs (ibuprofen, arthrotec, celecoxib,naproxen, rofecoxib) for treating OA.
We searched the Cochrane Controlled Trials Register (Issue 3, 2002), MEDLINE (up to July 2002), and Current Contents (up to March 2002). Reference lists of identified RCTs and pertinent review articles were also hand searched.
Published randomized controlled trials (RCTs) evaluating the efficacy and safety of acetaminophen alone in OA were considered for inclusion.
Pain, physical function and global assessment outcomes were reported. Results for continuous outcome measures were expressed as standardized mean differences. Dichotomous outcome measures were pooled using relative risk and the number needed to treat was calculated.
Six RCTs and 1689 participants were included in the review. One study compared acetaminophen to placebo, and five compared acetaminophen to NSAIDs. In the placebo-controlled RCT, acetaminophen was shown to be clearly superior to placebo with a similar safety profile. The number needed to treat to achieve an improvement in pain was three. In the comparator-controlled RCTs, acetaminophen was less effective overall than NSAIDs in terms of pain reduction and global assessments but both drugs had similar efficacy in terms of improvements in functional status. No significant difference was found between the safety of acetaminophen and NSAIDs, although patients taking NSAIDS were more likely to withdraw due to GI events.
REVIEWER'S CONCLUSIONS: The evidence to date suggests that NSAIDs are superior to acetaminophen for improving knee and hip pain in people with OA but have not been shown to be superior in improving function. The size of the treatment effect was modest, and the mean trial duration was only six weeks, therefore, additional considerations need to be factored in when making the decision between using acetaminophen or NSAIDs. In OA subjects with moderate-to-severe levels of pain, NSAIDs appear to be more effective than acetaminophen.
骨关节炎(OA)是最常见的关节炎形式。已发表的指南和专家意见对于对乙酰氨基酚(也称为扑热息痛或泰诺林)和非甾体抗炎药(NSAIDs)作为一线药物治疗的相对作用存在分歧。考虑对乙酰氨基酚和NSAIDs的比较安全性很重要,因为NSAIDs有导致严重胃肠道、肾脏和心血管毒性的可能性,而高剂量(每天大于或等于2克)的对乙酰氨基酚也可能有导致严重上消化道毒性的可能性。
评估对乙酰氨基酚与安慰剂以及与NSAIDs(布洛芬、奥湿克、塞来昔布、萘普生、罗非昔布)治疗OA的疗效和安全性。
我们检索了Cochrane对照试验注册库(2002年第3期)、MEDLINE(截至2002年7月)和《现刊目次》(截至2002年3月)。还手工检索了已识别的随机对照试验(RCTs)的参考文献列表和相关综述文章。
纳入已发表的评估对乙酰氨基酚单独治疗OA的疗效和安全性的随机对照试验(RCTs)。
报告了疼痛、身体功能和整体评估结果。连续结果测量的结果以标准化均数差值表示。二分结果测量采用相对危险度合并,并计算治疗所需人数。
该综述纳入了6项RCTs和1689名参与者。一项研究将对乙酰氨基酚与安慰剂进行了比较,五项研究将对乙酰氨基酚与NSAIDs进行了比较。在安慰剂对照的RCT中,对乙酰氨基酚显示明显优于安慰剂,且安全性相似。实现疼痛改善所需的治疗人数为3人。在对照药物对照的RCTs中,就减轻疼痛和整体评估而言,对乙酰氨基酚总体上不如NSAIDs有效,但两种药物在功能状态改善方面疗效相似。对乙酰氨基酚和NSAIDs的安全性未发现显著差异,尽管服用NSAIDs的患者因胃肠道事件更有可能退出试验。
迄今为止的证据表明,NSAIDs在改善OA患者的膝关节和髋关节疼痛方面优于对乙酰氨基酚,但在改善功能方面未显示更优。治疗效果的大小适中,且试验平均持续时间仅为六周,因此,在决定使用对乙酰氨基酚或NSAIDs时需要考虑其他因素。在疼痛程度为中度至重度的OA患者中,NSAIDs似乎比对乙酰氨基酚更有效。